| Literature DB >> 31876783 |
Rosario Maggiore1, Alice Grossi2, Francesca Fioredda1, Elena Palmisani1, Paola Terranova1, Enrico Cappelli1, Tiziana Lanza1, Filomena Pierri1, Daniela Guardo1, Michaela Calvillo1, Concetta Micalizzi1, Andrea Beccaria1, Maria C Coccia3, Serena Arrigo4, Carlo Dufour1, Isabella Ceccherini2, Maurizio Miano1.
Abstract
In recent years, monogenic causes of immune dysregulation syndromes, with variable phenotypes, have been documented. Mutations in the lipopolysaccharide-responsive beige-like anchor (LRBA) protein are associated with common variable immunodeficiency, autoimmunity, chronic enteropathy, and immune dysregulation disorders. The LRBA protein prevents degradation of cytotoxic T-lymphocyte antigen 4 (CTLA4) protein, thus inhibiting immune responses. Both LRBA and CTLA4 deficiencies usually present with immune dysregulation, mostly characterized by autoimmunity and lymphoproliferation. In this report, we describe a patient with an atypical clinical onset of LRBA deficiency and the patient's response to abatacept, a fusion protein-drug that mimics the action of CTLA4.Entities:
Year: 2020 PMID: 31876783 DOI: 10.1097/MPH.0000000000001708
Source DB: PubMed Journal: J Pediatr Hematol Oncol ISSN: 1077-4114 Impact factor: 1.289